MOESM6 of Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer
收藏数据链接：
官方服务：
资源简介：
Additional file 6: File S1. Ingenuity pathway analysis of the HBCx34 OvaR PDX models at the end of the study.
创建时间：
2019-12-04
